COVID Products – Directly Sourced From Manufacturers

 We are the leading Covid products supplier and export all products like PPE kit, face shield, Nitrile gloves, N95 masks, and all other essential covid products

 Question: Do you imagine that these revision processes in the health care supply chain continue to be strained due to the high demand for Personal Protective Equipment (PPE) at home and abroad, in the months of the COVID-19 pandemic. While sourcing PPE remains a challenge for many health care supply chain professionals, coordination within the health care sector has improved significantly, resulting in strategic partnerships to improve access to essential supplies while adding clarity to the vendor-waiting process Is.

 Mike Schiller, senior director of supply chain for the Association for Health Care Resources and Materials Management (AHRMM), discusses the past, present and future state of the health care supply chain during the COVID-19 pandemic.

Q: Political leaders often emphasize the need to end our dependence on foreign manufacturers for a wide variety of goods, but especially for PPE. Have you noticed a tendency for providers to reevaluate their supply chains from overseas to domestic suppliers? And if so, do you think it's really a realistic endeavor?

Mike: Yes, I've heard this from conversations with coworkers and peers. Hospitals are looking to diversify their vendor portfolio as a whole and are looking at a number of different ways to do so. One notable option that supply chain professionals are considering is moving to multi-source contracts as opposed to single-source contracts.

Based on my conversations with a few GPOs (Group Purchasing Organisations), this is an opportunity to reevaluate the contracting process. vaccine supplier  Domestic manufacturing brings with it the potential for increased supply costs on the road, but there seems to be an appetite for it in the face of the current environment.

Q: Along those lines, are you seeing that there are more "bad actors" in the products that offer space that are either of low quality or not present at all?

Mike: Yes. In early March, there was a significant increase in emails from non-traditional, or gray, manufacturers and suppliers claiming access to quality PPE with each of these manufacturers and suppliers.

The reality is that there are poor quality products that are sold in the U.S. have entered the health supply chain. Providers were required to take action to provide access to PPE, and the FDA through issuing an Emergency Use Authorization (EUA) permitting temporary use of non-FDA-approved products. Unfortunately, there are some bad actors in this field who either never shipped their products or didn't send bad/poor quality products.

Q: Has AHRMM taken any steps to help supply chain professionals through these gray manufacturers and suppliers?

Mike: At AHRMM, we started out acting as the clearinghouse for a hospital supply chain professional. We worked with a third-party partner, Vendormate, who offered to collaborate to allow us access to their vendor-revision program. As we received email requests from these gray manufacturers and suppliers; medical product distributors We can provide an initial high-level review - called the FACIS Level 1M review. Vendors that we consider acceptable, based on the waiting report, will be listed on the AHRMM COVID-19 resource website. To date, we have screened over 800 of these vendors and there are over 300 that are approved and listed on our website.


Comments

Post a Comment

Popular posts from this blog

Hertraz (Trastuzumab): Revolutionizing Breast Cancer Treatment

Image
 Hertraz (Trastuzumab): Revolutionizing Breast Cancer Treatment Introduction: Breast cancer is one of the most prevalent and life-threatening diseases affecting women worldwide. However, significant strides have been made in the field of oncology to develop targeted therapies that improve patient outcomes. Hertraz, a groundbreaking medication based on the monoclonal antibody trastuzumab, has emerged as a game-changer in the treatment of HER2-positive breast cancer. This blog explores the efficacy, benefits, and future prospects of Hertraz in revolutionizing breast cancer treatment. Understanding Hertraz: Hertraz is a therapeutic drug that harnesses the power of trastuzumab, a monoclonal antibody that specifically targets HER2-positive breast cancer cells. HER2-positive breast cancer is characterized by an overexpression of the HER2 protein, which promotes cancer cell growth. By binding to HER2 receptors, Hertraz inhibits the growth and spread of cancer cells while enhancing the effecti
Read more

Midostar-Midostaurin: A Promising Breakthrough in Cancer Treatment

Image
  Introduction: Cancer continues to be a formidable disease, affecting millions of lives worldwide. However, the field of oncology has witnessed significant advancements, leading to the development of targeted therapies that offer new hope for patients. One such breakthrough is Midostar-Midostaurin , a novel medication with immense potential in the treatment of certain types of cancers. In this blog post, we will explore the mechanism of action, clinical applications, and the future prospects of Midostar-Midostaurin. Understanding Midostar-Midostaurin: Midostar-Midostaurin belongs to a class of drugs known as kinase inhibitors. It specifically targets and inhibits certain enzymes called receptor tyrosine kinases, including FLT3 and KIT. These enzymes play a critical role in the growth and proliferation of cancer cells, particularly in acute myeloid leukemia (AML) and aggressive systemic mastocytosis (ASM). Clinical Applications: Acute Myeloid Leukemia (AML): AML is a fast-growing type
Read more

Direct to patient pharmacy

Image
 Making clinical preliminaries more tolerant-driven is among the many difficulties confronting the drug business. One technique for further developing the patient experience is by conveying concentrate taking drugs straightforwardly to patient homes, otherwise called Direct-to-Patient or DTP. Notwithstanding, the execution of Direct-to-Patient might appear to be unrealistic in a profoundly controlled industry where explicit guidelines or direction is missing or ambiguous. Moreover, Direct-to-Patient encounters can be conflicting by nation, preliminary, or helpful region.  Along these lines, in follow up to the peak blog entry, Developing a Guide for Patient-Centric Logistics - Get Involved1 a working together with a group of Direct-to-Patient Sponsors, Couriers, CROS, and QPs will, through a progression of web journals, distinguish a portion of the direct-to-patient models, share contemplations for building up a Direct-to-Patient program according to the partners' point of view and
Read more